Who owns ImmunityBio, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of IBRX from SEC Form 13F filings across 405 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 405 institutions disclosed 207.1M shares of ImmunityBio, Inc. worth $1.95B — about 19.5% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
405
13F holders
$1.95B
value, 2026 filers
19.5%
of shares outstanding (207.1M sh)
56
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of IBRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 36.1M | $341.0M | 0.0% | 3.4% | +6.0% |
| 2 | STATE STREET CORP | 21.1M | $199.1M | 0.0% | 2% | -1.4% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 19.4M | $183.0M | 0.0% | 1.8% | +8.5% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 18.8M | $177.5M | 0.0% | 1.8% | +19.8% |
| 5 | D. E. Shaw & Co., Inc. | 10.7M | $101.1M | 0.0% | 1% | -7.3% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 10.6M | $100.1M | 0.0% | 1% | +7.7% |
| 7 | TWO SIGMA INVESTMENTS, LP | 5.8M | $55.0M | 0.0% | 0.5% | -47.5% |
| 8 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.9M | $46.6M | 0.0% | 0.5% | +70.8% |
| 9 | GOLDMAN SACHS GROUP INC | 4.1M | $39.0M | 0.0% | 0.4% | +27.7% |
| 10 | MILLENNIUM MANAGEMENT LLC | 3.8M | $36.0M | 0.0% | 0.4% | -31.6% |
| 11 | UBS Group AG | 3.8M | $35.6M | 0.0% | 0.4% | +18.1% |
| 12 | NORTHERN TRUST CORP | 3.7M | $34.9M | 0.0% | 0.3% | +3.6% |
| 13 | VANGUARD FIDUCIARY TRUST CO | 2.8M | $26.9M | 0.0% | 0.3% | +18.1% |
| 14 | SEB Asset Management AB | 2.4M | $23.1M | 0.1% | 0.2% | 0.0% |
| 15 | MORGAN STANLEY | 2.1M | $20.1M | 0.0% | 0.2% | -37.9% |
| 16 | FEDERATED HERMES, INC. | 2.0M | $18.5M | 0.0% | 0.2% | +14.3% |
| 17 | ROYAL BANK OF CANADA | 2.0M | $18.4M | 0.0% | 0.2% | +26.5% |
| 18 | Woodline Partners LP | 1.9M | $17.9M | 0.1% | 0.2% | -24.1% |
| 19 | PRINCIPAL FINANCIAL GROUP INC | 1.7M | $16.4M | 0.0% | 0.2% | +5779.0% |
| 20 | BANK OF AMERICA CORP /DE/ | 1.7M | $16.3M | 0.0% | 0.2% | -21.1% |
| 21 | JPMORGAN CHASE & CO | 1.5M | $13.1M | 0.0% | 0.1% | +1.2% |
| 22 | MARSHALL WACE, LLP | 1.5M | $13.7M | 0.0% | 0.1% | +274.1% |
| 23 | Bank of New York Mellon Corp | 1.3M | $12.4M | 0.0% | 0.1% | +0.1% |
| 24 | Trexquant Investment LP | 1.3M | $12.4M | 0.1% | 0.1% | +88.6% |
| 25 | Cetera Investment Advisers | 1.2M | $11.5M | 0.0% | 0.1% | +7.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.